Research, Select, & Monitor Friday, July 10, 2020 7:39:37 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
ImmunoGen, Inc.$4.82$.153.21%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
   Thursday, April 18, 2019 4:30:00 PM ET

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019 to discuss its first quarter operating results. Management will also provide a brief update on the business.

Conference Call Information
To access the live call by phone, dial 323-994-2093; the conference ID is 8980567. The call may also be accessed through the Investors and Media section of the Company’s website, . Following the webcast, a replay of the call will be available at the same location through May 17, 2019.

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.

Learn more about who we are, what we do, and how we do it at .

Sarah Kiely

Courtney O’Konek


FTI Consulting
Robert Stanislaro

Source: ImmunoGen, Inc.

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.